English
Back
Download
Log in to access Online Inquiry
Back to the Top

avatar
74502850 Private ID: 74502850
No profile added yet
Follow
    74502850 reacted to and commented on
    $Esperion Therapeutics (ESPR.US)$Undervalued Stock with a Game-Changing Statin Alternative
    This is a $0.73 stock with a market cap of approximately $145 million — offering significant upside potential. The company, Esperion Therapeutics, sells two FDA-approved, much-needed statin alternatives: Nexletol and Nexlizet. These medications address a major health need — millions of patients cannot tolerate statins due to side effects but still need to m...
    Esperion Therapeutics SCREAMS Short Selling Scheme
    8
    1
    74502850 reacted to and commented on
    $Esperion Therapeutics (ESPR.US)$Esperion's Promising Future: Strategic Partnerships and Product Innovations Drive Buy Rating
    Esperion (ESPR Research Report), the Healthcare sector company, was revisited by a Wall Street analyst . Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and has a $9.00 price target.
    Thomas Shrader has given his Buy rating due to a combination ...
    4 Star analyst Buy Rating $9 Target On This Dirt Cheap Stock Is 500% Upside, And 5 Star Analyst Sees $8
    4 Star analyst Buy Rating $9 Target On This Dirt Cheap Stock Is 500% Upside, And 5 Star Analyst Sees $8
    4 Star analyst Buy Rating $9 Target On This Dirt Cheap Stock Is 500% Upside, And 5 Star Analyst Sees $8
    4
No more